本文選題：miR-125 + 非小細胞肺癌　； 參考：《遵義醫(yī)學院》2017年碩士論文

【摘要】：目的:研究mi R-125在非小細胞肺癌患者EGFR-TKIs耐藥前、后血清中的表達,探討其對EGFR-TKIs療效的預測價值。方法:通過實時熒光定量RT-PCR法檢測36例EGFR-TKIs耐藥前、20例耐藥后的EGFR突變陽性的晚期肺腺癌患者及13例肺部良性疾病患者的血清標本中mi R-125a-5p及mi R-125b的表達水平。對接受EGFR-TKIs治療的NSCLC患者進行隨訪及近期療效評價。結果:1.EGFR-TKIs耐藥前組1.058(0.506~2.313)和耐藥后組0.603(0.286~1.154)血清中mi R-125a-5p的表達量均較肺部良性疾病組2.174(1.655~3.317)顯著降低(P=0.014,P=0.000)。耐藥后組對比耐藥前組mi R-125a-5p的表達量顯著降低,差異具有統(tǒng)計學意義(P=0.045)。血清中mi R-125b的表達量在耐藥前組1.025(0.441~2.957)和耐藥后組1.684(1.021~2.532)對比肺部良性疾病組2.122(1.846~3.12)無統(tǒng)計學差異(P=0.074,P=0.456),耐藥前與耐藥后組比較差異無統(tǒng)計學意義(P=0.259)。在3例耐藥前、后的配對血清樣本中,mi R-125a-5p和mi R-125b的表達均在耐藥后出現(xiàn)下降。2.在EGFR-TKIs耐藥患者血清中,mi R-125a-5p和mi R-125b在T790M突變組和未突變組中表達無顯著差異(P=0.877,P=0.280)。3.治療失敗組mi R-125a-5p和mi R-125b較治療緩解組表達均出現(xiàn)低表達,但無統(tǒng)計學差異(P=0.290,P=0.264)。結論:1.血清中mi R-125a-5p的低表達可能與NSCLC的EGFR-TKIs耐藥相關,其可作為EGFR-TKIs耐藥的潛在標志物,還可作為EGFR-TKIs療效預測的有效指標。2.EGFR-TKIs耐藥患者血清中mi R-125在T790M突變組和未突變組中表達無顯著差異。
[Abstract]:Objective: to study the expression of miR-125 in serum of patients with non-small cell lung cancer (NSCLC) before and after EGFR-TKIs resistance, and to explore its predictive value for the efficacy of EGFR-TKIs. Methods: the expression of miR-125a-5p and miR-125b in serum of 36 patients with EGFR-TKIs with EGFR mutation positive and 13 patients with pulmonary benign diseases were detected by real-time quantitative RT-PCR. The patients with NSCLC receiving EGFR-TKIs were followed up and the short-term efficacy was evaluated. Results the expression of miR-125a-5p in the pre- and post-drug resistant group of 1.EGFR-TKIs was significantly lower than that in the benign pulmonary disease group (2.174 ~ 1.655 / 3.317), and the expression of miR-125a-5p in the serum of the former group was significantly lower than that of the benign pulmonary disease group (0.603) and that of the post-drug resistant group (0.603 ~ 0.154) was significantly lower than that of the benign pulmonary disease group. The expression of miR-125a-5p was significantly decreased in the resistant group compared with that in the pre-resistant group, and the difference was statistically significant (P < 0.05). There was no significant difference in the expression of miR-125b between the pre-drug resistant group (1.025) 0.441U 2.957) and the post-resistant group (1.684 ~ 1.021 ~ 2.532) compared with the benign pulmonary disease group (2.122 ~ 1.846 ~ 3.12). There was no significant difference between the pre-drug resistance group and the post-drug resistance group (P = 0.259). The expression of miR-125a-5p and miR-125b in the serum samples of 3 patients before and after drug resistance decreased after drug resistance. There was no significant difference in the expression of mil R-125a-5p and mi R-125b between the T790M mutant group and the non-mutant group in the serum of EGFR-TKIs resistant patients. The expression of mi R-125a-5p and mi R-125b in the failed group was lower than that in the remission group, but there was no statistical difference between the two groups. Conclusion 1. The low expression of miR-125a-5p in serum may be associated with EGFR-TKIs resistance of NSCLC, which can be used as a potential marker of EGFR-TKIs resistance and as an effective index for predicting the efficacy of EGFR-TKIs. 2.The expression of miR-125 in serum of patients with EGFR-TKIs resistance has no significant difference between the T790M mutation group and the non-mutant group.
【學位授予單位】：遵義醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R734.2

【相似文獻】

相關期刊論文 前10條

1 李丹,曾波航,鄔勇堅;晚期肺癌和肺部良性疾病患者血漿纖維蛋白原水平與功能的研究[J];血栓與止血學;2001年01期

2 劉卓;;肺部良性疾病誤診肺癌21例臨床分析[J];實用醫(yī)院臨床雜志;2006年05期

3 朱雪娟;;胸腔鏡肺部良性疾病術后不置胸管的圍手術期護理配合[J];臨床肺科雜志;2012年12期

4 陳福全,吳一龍;肺部良性疾病68例誤診為肺癌分析[J];臨床誤診誤治;1998年06期

5 包國良,董強剛,馮久賢,江曉豐,沙慧芳,顧偉勇,許凱黎;肺癌患者血漿中血管內皮生長因子與堿性纖維母細胞生長因子表達[J];腫瘤;2002年02期

6 王光義,王玉民;肺部良性疾病誤診為肺癌5例[J];菏澤醫(yī)專學報;1996年01期

7 邵輝;張瑩;;肺癌患者血CEA、CA199及ACTH的聯(lián)合檢測[J];遼寧醫(yī)學雜志;2006年02期

8 仇鐵峰;丁明;李獻文;金建華;;Skp2 mRNA在肺癌中的表達及意義[J];海南醫(yī)學院學報;2014年03期

9 胡躍,李旭芬,張?zhí)K展;肺癌患者外周血中CK19-mRNA表達的檢測[J];實用癌癥雜志;2004年01期

10 于學燕;張靜;郭帥;;肺部良性疾病及晚期肺癌患者血漿纖維蛋白原水平變化及意義[J];山東醫(yī)藥;2013年22期

相關會議論文 前4條

1 應可凈;邵方淳;余碧蕓;吳金民;丁佳逸;;肺癌活檢組織中PLK1 mRNA水平的定量檢測[A];2005年浙江省內科學學術年會論文匯編[C];2005年

2 溫開鎮(zhèn);張忠英;;熒光定量聚合酶鏈反應檢測肺癌患者血漿循環(huán)DNA及其臨床意義[A];中華醫(yī)學會第七次全國檢驗醫(yī)學學術會議資料匯編[C];2008年

3 張鶴;劉紅兵;袁冬梅;王兆峰;王允芬;宋勇;;SPP1表達量可提示肺癌所致MPE患者的預后[A];第13屆全國肺癌學術大會論文匯編[C];2013年

4 陳周苗;何啟才;王永清;酈志軍;葉偉文;;全胸腔鏡下肺葉切除治療肺部良性疾病[A];2008年浙江省胸心外科學學術年會暨浙江省醫(yī)學會胸心外科學分會體外循環(huán)學組、胸腔鏡學組成立大會論文匯編[C];2008年

相關博士學位論文 前1條

1 謝廣順;血漿DNA定量測定及p16基因異常甲基化分析在肺癌診斷中的意義[D];中國協(xié)和醫(yī)科大學;2004年

相關碩士學位論文 前3條

1 溫華;常壓直接質譜分析技術快速診斷肺癌的分子基礎研究[D];南昌大學醫(yī)學院;2015年

2 王怡;miR-125在NSCLC EGFR-TKIs耐藥前后血清中的表達及其臨床意義[D];遵義醫(yī)學院;2017年

3 鄒慎春;MDA-7在NSCLC中的表達及其臨床意義[D];青島大學;2006年

，

本文編號：2044130